homepage-top-section

It is the fourth Sandoz biosimilar approved in Europe in past 18 months, and seventh in total. Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein

GSK said the committee voted on the basis of data presented that the risk-benefit profile was not adequate to support approval In addition, the committee noted that there

The trial is one of the two phase 1 safety clinical studies of the drug examining its potential to cause dermal irritation. XF-73 is Destiny Pharma’s lead candidate

The company will build the new multi-storey and 400,000ft² production facility in Portage, situated in Kalamazoo County. Named as modular aseptic processing (MAP), the new production facility will

The chemotherapy used in combination with Tecentriq is Abraxane [albumin-bound paclitaxel; nab-paclitaxel]). The late-stage trial dubbed IMpassion130 was found to have reduced the risk of disease worsening or

The companies announced that they had entered into exclusive talks on April 17, 2018. The signing of this Share Purchase Agreement marks a critical step on the way

Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion